FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

EA McKie

Research Profile

Living Beings

Concepts & Ideas

Virulence

Disorders

Procedures

Genetic Therapy

Physiology

Chemicals & Drugs

Anatomy

Genes & Molecular Sequences

Genes, Viral

Co-author Network

Publications

TOP 3
Roy Rampling; Garth Cruickshank; Vakis Papanastassiou; Nicoll James; Donald M Hadley; David Brennan; R Petty; A MacLean; June Harland; EA McKie; R Mabbs; M Brown
Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma.
EA McKie; SM Brown; A R MacLean; D I Graham
Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevance for gene and cancer therapy.
EA McKie; D I Graham; SM Brown
Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RL1 null mutant vector--potential glioblastoma targeting.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of EA McKie (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2000: Roy Rampling; Garth Cruickshank; Vakis Papanastassiou; Nicoll James; Donald M Hadley; David Brennan; R Petty; A MacLean; June Harland; EA McKie; R Mabbs; M Brown
Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma.
Gene therapy 2000;7(10):859-66.
1998: EA McKie; SM Brown; A R MacLean; D I Graham
Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevance for gene and cancer therapy.
Neuropathology and applied neurobiology 1998;24(5):367-72.
1998: EA McKie; D I Graham; SM Brown
Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RL1 null mutant vector--potential glioblastoma targeting.
Gene therapy 1998;5(4):440-50.
1997: SM Brown; A R MacLean; EA McKie; J Harland
The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyD116, and GADD34.
Journal of virology 1997;71(12):9442-9.
1996: EA McKie; A R MacLean; A D Lewis; G Cruickshank; Roy Rampling; Susan C Barnett; P G Kennedy; S M Brown
Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours--evaluation of a potentially effective clinical therapy.
British journal of cancer 1996;74(5):745-52.
1995: J G Spivack; M U Fareed; Tibor Valyi-Nagy; T C Nash; J S O'Keefe; R M Gesser; EA McKie; A R MacLean; Nigel W Fraser; S M Brown
Replication, establishment of latent infection, expression of the latency-associated transcripts and explant reactivation of herpes simplex virus type 1 gamma 34.5 mutants in a mouse eye model.
The Journal of general virology 1995;76 ( Pt 2)():321-32.
1994: EA McKie; R G Hope; S M Brown; A R MacLean
Characterization of the herpes simplex virus type 1 strain 17+ neurovirulence gene RL1 and its expression in a bacterial system.
The Journal of general virology 1994;75 ( Pt 4)():733-41.
1992: Aidan Dolan; EA McKie; A R MacLean; Duncan J McGeoch
Status of the ICP34.5 gene in herpes simplex virus type 1 strain 17.
The Journal of general virology 1992;73 ( Pt 4)():971-3.